Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys
20.4.2026 16:00:00 CEST | Business Wire | Press release
Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow.
SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/

PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications.
Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) and non-irradiated configurations — PETG PharmaTainer supports the full bioprocessing workflow. Standard and fully custom assemblies with Cap2V8® closures and Cellgyn™ TPE tubing are available for both open and closed operations. Start with PharmaTainer in early-stage R&D and carry the same platform through clinical and commercial phases — eliminating the need for requalification when scaling.
For part numbers, ordering information, and technical specifications, visit sanisure.com/petg or contact your SaniSure representative.
“With PETG PharmaTainer™, we are shifting cleanliness from a post-processing step to a fully automated, built-in standard - enabling us to confidently deliver the cleanest bioprocessing containers on the market for our customers’ most critical applications. Our bottles provide the lowest possible levels of particulates, endotoxins and RNase/DNase - by design - while minimizing adoption timelines.”
— Steven Chevillotte, CEO of SaniSure®
Cleaner by Design: What Sets PETG PharmaTainer™ Apart
Our PETG PharmaTainer delivers a validated suite of cleanliness and compliance attributes consistent with those of our PET and PC bottles:
- Ultra-Low Particle Levels: Certified to less than 5% of USP <788> limits for sub-visible particulates, tested at lot release — no post-wash required.
- Exceptional Endotoxin Control: Results consistently below 0.001 EU/mL detection limit per USP <85> — achieved by design, not by washing.
- RNase/DNase-Free Certified: Validated for nucleic acid-based therapies including mRNA, oligonucleotides, and gene therapy applications requiring contamination-critical containers.
- Ready-to-Use — Sterile: Gamma-sterilized to SAL 10⁻⁶, minimizing the 2–3 days of washing, depyrogenation, and sterilization steps typically required with competitive products, reducing labor and contamination risk.
- Freeze-Thaw Validated to −80°C: Suited for bulk drug substance cold chain, stability studies, and frozen intermediates across the full temperature range.
- Drop-In PETG Replacement: One-to-one volume and format compatibility with legacy PETG bioprocessing bottles; a comparability guide and dedicated technical support are included to minimize change-control burden.
About SaniSure®
As a trusted Single-Use Technologies (SUT) expert, SaniSure brings deep expertise in complex flow paths and closed-system design - supporting the most demanding bioprocessing and advanced therapy workflows. In addition to the PETG PharmaTainer, SaniSure provides a wide array of high-quality components, custom assemblies and SUT solutions.
Where larger organizations often lack flexibility and smaller providers lack scale, SaniSure delivers the best of both - combining agility with end-to-end capabilities and deep vertical integration to help customers de-risk, scale, and innovate.
Learn more at sanisure.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260420641769/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release
– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press release
Contributing to the International Manufacturing-X Council Showcase at Hannover Messe, to improve resilience, productivity and innovation in Manufacturing Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performanc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom